Vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin. It has a major psychosocial impact on affected patients. There are many treatment modalities available for vitiligo, however, none of them cure the disease. Topical corticosteroids (CS) are the most effective monotherapy for localized vitiligo. Treatment with intralesional corticosteroids (ILCS) is commonly used in many dermatologic conditions. However, there are only a few studies published on the use of ILCS in vitiligo. This is a prospective double-blind randomized clinical trial to assess efficacy and safety of ILCS in the treatment of vitiligo. Four treatment sessions will be done over 4 to 6 months. The investigators will compare intralesional triamcinolone acetonide (active treatment) to normal saline (placebo).
1 Primary · 1 Secondary · Reporting Duration: 3-5 weeks after each treatment session
18 Total Participants · 2 Treatment Groups
Primary Treatment: A: Triamcinolone acetonide · No Placebo Group · Phase 2
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: